相关实验视频
Updated: Jun 19, 2026

12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
12.6K
新诊断的CD5阳性扩散型大B细胞淋巴瘤的治疗方法和结果:一个多机构的观察性研究
Yuma Nato1,2, Kana Miyazaki2, Dai Maruyama3
1Department of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan.
Hematological oncology
|February 12, 2025
概括
剂量调整 (DA) -EPOCH-R和高剂量甲状腺酸盐 (HD-MTX) 化疗对CD5阳性扩散性大B细胞淋巴瘤 (CD5+DLBCL) 显示出有效的结果. 这种治疗提供了可管理的安全性,并可以预防CD5+DLBCL患者中中枢神经系统 (CNS) 复发.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- CD5阳性扩散性大B细胞淋巴瘤 (CD5+DLBCL) 是一种具有不良预后和中枢神经系统 (CNS) 复发高风险的侵袭性亚型.
- 之前的II期研究表明,用剂量调整 (DA) -EPOCH-R和高剂量甲状腺素 (HD-MTX) 的三明治疗法对CD5+DLBCL有效.
- 这种治疗方案的现实世界验证及其对中枢神经系统复发预防的影响对于临床实践至关重要.
研究的目的:
- 以追溯分析2016年至2021年期间诊断的CD5+DLBCL患者的大队伍中的治疗结果.
- 在现实环境中验证DA-EPOCH-R/HD-MTX的疗效和安全性.
- 确定整体存活期的独立风险因素,并评估HD-MTX和内甲铁酸 (IT-MTX) 在预防中枢神经系统复发中的作用.
主要方法:
- 对346名CD5+DLBCL患者的回顾性分析,这些患者接受了与rituximab. rituximab. rituximab. rituximab. rituximab. rituximab. rituximab.
- 用DA-EPOCH-R/HD-MTX和其他疗程治疗的患者之间的结局的比较.
- 多变量分析以确定总生存率和中枢神经系统复发的预后因素.
主要成果:
- 在接受DA-EPOCH-R/HD-MTX治疗的55名II-IV期CD5+DLBCL患者中,2年总生存率为87%,无进展生存率为76%.
- 中枢神经系统复发的累计发病率为DA-EPOCH-R/HD-MTX的7.3%,只有在接受HD-MTX和IT-MTX的患者中观察到一个中枢神经系统复发.
- 乳酸脱酶的升高,外干涉以及DA-EPOCH-R/HD-MTX或IT-MTX的缺失是导致整体生存时间差的独立风险因素.
结论:
- DA-EPOCH-R/HD-MTX疗法在CD5+DLBCL的真实临床环境中证明了经过验证的有利生存率和可管理的毒性.
- 在CD5+DLBCL患者中,HD-MTX和IT-MTX的组合似乎有效防止中枢神经系统复发.
- 这项研究提供了重要的现实数据,支持DA-EPOCH-R/HD-MTX作为CD5+DLBCL的首选治疗方法,特别是用于预防中枢神经系统复发.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

